Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa

This article was originally published in The Pink Sheet Daily

Executive Summary

With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.

You may also be interested in...



FDA Discounts Advisory Panel’s Advice, Says Lilly’s Depot Zyprexa “Not Approvable”

Agency seeks more information on olanzapine depot's sedation effect.

FDA Discounts Advisory Panel’s Advice, Says Lilly’s Depot Zyprexa “Not Approvable”

Agency seeks more information on olanzapine depot's sedation effect.

FDA Panel To Assess Excessive Sedation Linked To Lilly’s Zyprexa Depot Formulation

FDA Psychopharmacologic Drugs Advisory Committee will vote Feb. 6 on the safety and efficacy of the long-acting atypical antipsychotic.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel